Toronto startup Molagri has raised $5.8 million in pre-seed and seed funding to build biopesticides growers could effectively update as insects develop resistance. The round was led by Convective Capital, with participation from Superorganism, Y Combinator, Julian Capital and angel investors including Y Combinator cofounder Paul Graham.

For growers, the money funds an early bet on two of crop protection's oldest problems: resistance and collateral damage from broad-spectrum sprays. Cofounder Zaky Hassan frames the ambition in blunt terms.

"Farmers shouldn't have to worry about resistance, the same way you don't think about which flu strain is going around when you get a flu shot," Hassan said. "We want to be the team that designs the next product before resistance becomes a problem in the field."

How does the technology work?

The platform, developed by Hassan and cofounder Min Jin, uses engineered non-infectious virus-like particles, or VLPs. A target pest ingests the particle. Proteins on its surface bind to specific receptors in the insect's gut. The particle then enters the pest's cells and delivers mRNA instructions that prompt those cells to produce a toxin, killing the insect from within.

Beneficial insects, including pollinators, lack the receptor. That is the theory. Molagri has used cryogenic electron microscopy to map a receptor in honeybees, identifying structural differences that could let targeting proteins bind to pests while leaving bees alone. The company has not yet demonstrated that selectivity in commercial field conditions, Hassan acknowledged.

"At a minimum, our payloads will be safe for honeybees, beneficials and vertebrates, even without the delivery gating by the VLPs," he said. "We aim to achieve highly specific delivery with the VLP, as well as payload specificity, although the payload specificity will be broader than the VLP specificity."

What does 'updatable' mean for resistance management?

The platform is modular. If a pest evolves a mutation that defeats the insecticidal payload, Molagri could swap in one acting through a different mechanism. If the pest changes the receptor the particle uses to enter cells, the company could redesign the targeting protein to match. Longer term, Molagri wants to monitor insect populations for emerging resistance mutations and design alternatives before the problem spreads in the field.

The approach could also allow growers to rotate between different modes of action against the same pest. That is a familiar resistance-management strategy, but one constrained today by the slow pace of new chemistry reaching the market.

What does this change for growers?

Not much yet, and Hassan is candid about it. The technology remains at an early stage. Molagri has determined the molecular structures of relevant insect receptors and is now developing its first virus-like particles for testing. Commercial performance, manufacturing costs, formulation stability and field efficacy have yet to be established. The company has secured one letter of intent from a grower.

Initial targets are high-value specialty crops: navel orangeworm, a major pest of almonds and pistachios, and codling moth, a significant problem in apples. Hassan also sees longer-term opportunities in commodity crops such as corn and canola.

The regulatory question

The business model depends heavily on how regulators treat the technology. If every updated version of the platform requires a full new pesticide registration, much of the benefit of rapid redesign could be lost. Molagri hopes to explore a pathway under which modifications to an established platform face review short of a complete new registration. Hassan acknowledges the company is still exploring what that would mean in practice.

Molagri has filed a provisional patent covering its targeted VLP delivery system and recently moved into a Toronto laboratory with biomanufacturing and tissue culture facilities. The new funding will support recruitment of scientists in insect biology, virology and VLP production, with manufacturing planned through yeast fermentation. Licensing to established crop protection companies is among the options for its first products.

Bill Clerico, managing partner at Convective Capital, said the bet rests on the widening gap between pest adaptation and the current toolbox. "Pesticide resistance is a slow-moving disaster for global food security, and the tools farmers have today weren't built for a world where pests adapt this quickly," he said. "Zaky and Min are bringing the precision of modern protein engineering to agriculture. We think this platform can give growers a durable, targeted alternative to broad-spectrum chemicals."

Whether that durability survives both field trials and the registration process will determine whether the $5.8 million becomes a down payment on a new crop protection category or another early-stage platform that never leaves the lab.